Roche signs discovery partnerships with Atavistik Bio and Earendil Labs

Roche announced new collaborations with the drug discovery companies Atavistik Bio and Earendil Labs to develop early-stage candidates.

The agreements continue a recent wave of dealmaking by the Swiss group, adding to several partnerships announced in the past two months.

Both biotechs will receive Roche's resources to advance promising molecules, with the goal of expanding the company's pipeline.

The moves are intended to broaden Roche's therapeutic reach and may be of interest to investors tracking the firm's growth strategy.